

## Referenties

1. Jeffrey D. Campbell , Bruce J. Trock, Adam R. Oppenheim, Ifeanyichukwu Anusionwu RAG and ALB. Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction Jeffrey. *Ther Adv Urol.* 2019;9(6):1–13. doi:10.1177/https
2. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU Guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism. *Eur Assoc Urol.* 2016:1–86.
3. De Boer BJ, Bots ML, Lycklama A Nijeholt AAB, Moors JPC, Pieters HM, Verheij TJM. Erectile dysfunction in primary care: Prevalence and patient characteristics. The ENIGMA study. *Int J Impot Res.* 2004;16(4):358–364. doi:10.1038/sj.ijir.3901155
4. Shamloul R, Ghanem H. Erectile dysfunction. *Lancet.* 2013;381(9861):153–165. doi:10.1016/S0140-6736(12)60520-0
5. Porst H. Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie’s Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different . *Sex Med Rev.* 2021;9(1):93–122. doi:10.1016/j.sxmr.2020.01.006
6. Feng S, Zhou L, Liu Q, e.a. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma? *Med (United States).* 2018;97(3). doi:10.1097/MD.0000000000009601
7. Madeira CR, Tonin FS, Fachi MM, e.a. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. *World J Urol.* 2021;39(3):953–962. doi:10.1007/s00345-020-03233-9
8. Angulo JC, Arance I, de las Heras MM, Meilán E, Esquinas C, Andrés EM. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. *Actas Urol Esp.* 2017;41(8):479–490. doi:10.1016/j.acuro.2016.07.005
9. Bakr AM, El-Sakka AI. Extracorporeal Shockwave Therapy in Peyronie’s Disease: Systematic Review and Meta-Analysis. *J Sex Med.* 2021;18(10):1705–1714. doi:10.1016/j.jsxm.2021.06.012
10. Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. *Int J Impot Res.* 2019;31(3):177–194. doi:10.1038/s41443-019-0117-z
11. Yao H, Wang X, Liu H, e.a. Systematic Review and Meta-Analysis of 16 Randomized Controlled Trials of Clinical Outcomes of Low-Intensity Extracorporeal Shock Wave Therapy in Treating Erectile Dysfunction. *Am J Mens Health.* 2022;16(2). doi:10.1177/15579883221087532
12. Man L, Li G. Low-intensity Extracorporeal Shock Wave Therapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. *Urology.* 2018;119:97–103.

doi:10.1016/j.urology.2017.09.011

13. Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. *Eur Urol*. 2017;71(2):223–233. doi:10.1016/j.eururo.2016.05.050
14. Dong L, Chang D, Zhang X, et al. Effect of Low-Intensity Extracorporeal Shock Wave on the Treatment of Erectile Dysfunction: A Systematic Review and Meta-Analysis. *Am J Mens Health*. 2019;13(2). doi:10.1177/1557988319846749
15. Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. *J Sex Med*. 2017;14(1):27–35. doi:10.1016/j.jsxm.2016.11.001
16. Brunckhorst O, Wells L, Teeling F, Muir G, Muneer A, Ahmed K. A systematic review of the long-term efficacy of low-intensity shockwave therapy for vasculogenic erectile dysfunction. *Int Urol Nephrol*. 2019;51(5):773–781. doi:10.1007/s11255-019-02127-z
17. Wu YT, Chang CN, Chen YM, Hu GC. Comparison of the effect of focused and radial extracorporeal shock waves on spastic equinus in patients with stroke: A randomized controlled trial. *Eur J Phys Rehabil Med*. 2018;54(4):518–525. doi:10.23736/S1973-9087.17.04801-8
18. Sokolakis I, Dimitriadis F, Teo PC pd., Hatzichristodoulou G, Hatzichristou D, Giuliano F. The Basic Science Behind Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction: A Systematic Scoping Review of Pre-Clinical Studies. *J Sex Med*. 2019;16(2):168–194. doi:10.1016/j.jsxm.2018.12.016
19. Chung E, Cartmill R. Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: An Australian first open-label single-arm prospective clinical trial. *BJU Int*. 2015;115(S5):46–49. doi:10.1111/bju.13035
20. Kitrey ND, Vardi Y, Appel B, et al. Low Intensity Shock Wave Treatment for Erectile Dysfunction—How Long Does the Effect Last? *J Urol*. 2018;200(1):167–170. doi:10.1016/j.juro.2018.02.070
21. Sandoval-Salinas C, Saffon JP, Corredor HA, Fonseca L, Manrique L, Solis G. Are Radial Pressure Waves Effective in Treating Erectile Dysfunction? A Systematic Review of Preclinical and Clinical Studies. *Sex Med*. 2021;9(4). doi:10.1016/j.esxm.2021.100393
22. Ortac M, Özmez A, Cilesiz NC, Demirelli E, Kadioğlu A. The impact of extracorporeal shock wave therapy for the treatment of young patients with vasculogenic mild erectile dysfunction: A prospective randomized single-blind, sham controlled study. *Andrology*. 2021;9(5):1571–1578. doi:10.1111/andr.13007
23. Olsen AB, Persiani M, Boie S, Hanna M, Lund L. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. *Scand J Urol*. 2015;49(4):329–333. doi:10.3109/21681805.2014.984326
24. Chung E, Cartmill R. Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile

dysfunction: An Australian first open-label single-arm prospective clinical trial. *BJU Int.* 2015;115(S5):46–49. doi:10.1111/bju.13035

25. Tsai CC, Wang CJ, Lee YC, e.a. Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors. *Am J Mens Health.* 2017;11(6):1781–1790. doi:10.1177/1557988317721643

